Biotech

All Articles

BMS channels TIGIT, leaving $200M bet on Agenus bispecific

.Bristol Myers Squibb is actually axing yet another large wager from the Caforio period, ending a pa...

Nuvation stops BET inhibitor after thinking about phase 1 information

.After checking out at phase 1 information, Nuvation Biography has made a decision to halt service i...

' Professional intuition' led FDA specialists to back Zevra's rare condition med

.Zevra Therapeutics' rare illness medicine seems to be on the road to authorization this fall after ...

Pfizer takes $230M hit after axing fell short DMD gene therapy

.Pfizer's stage 3 Duchenne muscle dystrophy (DMD) genetics treatment failure has actually gone a $23...

AC Immune finds 'landmark' prospective in Alzheimer's medicine records

.After much more than 20 years of focus on neurodegenerative ailments, Swiss biotech hvac Immune sys...

GSK falls ph. 2 HPV vaccination over shortage of best-in-class prospective

.GSK has junked a stage 2 human papillomavirus (HPV) vaccine coming from its own pipeline after choo...

OS Treatments refiles $6M IPO to finance HER2 medicine, preclinical ADCs

.OS Therapies will certainly detail on the NYSE American sell exchange today by means of a $6.4 thou...

ALX's fizzling CD47 response rate sends supply spiraling down

.ALX Oncology's stage 2 gastric cancer feedback rate has actually compromised. After viewing its own...

Ionis axes eye illness from aim ats of Roche-partnered possibility after information dissatisfy

.Another of Ionis Pharmaceuticals' key midphase readouts has disappointed requirements, cuing the bi...

Biogen's chief executive officer mentioned no high-risk handle 2023. He's ready to become daring

.While Biogen's pharma peers are searching for late-stage assets along with little bit of threat, CE...